TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02243709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone 600-mg/day or placebo for a week
Description: 600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mifepristone 600-mg/day or placebo for a week
Description: 600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine
Study: NCT03912207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Saline is a routinely used placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Saline is a routinely used placebo.
Study: NCT04207814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological sample
Description: biological samples will be taken from the subjects included
Study: NCT03912207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Saline is a routinely used placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Saline is a routinely used placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Saline is a routinely used placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Saline is a routinely used placebo.
Study: NCT02097121

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOTOX®
Description: Each vial of BOTOX (Botulinum Toxin Type A) purified neurotoxin complex, formulation No. 9060X contains 100 U of Clostridium botulinum toxin Type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. The study medication was to be reconstituted with 0.9% sodium chloride (preservative-free). The 10 mL of study drug was to be administered as 20 injections each of 0.5 mL. Under direct cystoscopic visualization, injections were to be distributed evenly across the detrusor wall and spaced approximately 1 cm apart. To avoid injecting the trigone, the injections were to be at least 1 cm above the trigone. The injection needle was to be inserted approximately 2 mm into the detrusor for each injection.
Study: NCT02735525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone monitoring
Description: Patients will be trained to use the smartphone and the wound surveillance app prior to discharge. Patients will use the app from home to take send digital images of their postoperative wounds and answer a short survey, all of which will be transmitted to a secure database maintained by the UW Department of Surgery and accessible only to UW-employed study personnel. These data will be evaluated by one of three vascular surgery service nurse practitioners (NPs) daily. Patients who have concerning findings either in their images or in their survey answers will be contacted for further evaluation.
Study: NCT03939780

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F18]RO-948
Description: Single radiotracer IV injection with subsequent emission scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F18]RO-948
Description: Single radiotracer IV injection with subsequent emission scan
Study: NCT02494986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Description: Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other ARVs.
Study: NCT03422302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphasic Positive Airway Pressure
Description: Receive BiPAP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT simulation scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: Receive CPAP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Inspiration Breath Hold
Description: Complete DIBH

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy Treatment Planning and Simulation
Description: Undergo CT simulation scans

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT03232073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod
Description: Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15
Study: NCT03939780

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F18]RO-948
Description: Single radiotracer IV injection with subsequent emission scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F18]MK-6240
Description: Single radiotracer IV injection with subsequent emission scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F18]MK-6240
Description: Single radiotracer IV injection with subsequent emission scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F18]MK-6240
Description: Single radiotracer IV injection with subsequent emission scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F18]AV1451
Description: Single radiotracer IV injection with subsequent emission scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F18]AV1451
Description: Single radiotracer IV injection with subsequent emission scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F18]AV1451
Description: Single radiotracer IV injection with subsequent emission scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F18]AV1451
Description: Single radiotracer IV injection with subsequent emission scan
Study: NCT03702010

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spinal cord stimulation conventional
Description: If the patient has been assigned to the branch of the CME control group, after mapping the search for the pain zone, the neurostimulator is programmed to conventional stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal cord stimulation experimental
Description: If the patient has been randomized to the branch of the EME experimental group, after a mapping of the search for the pain zone, a 90% subthreshold stimulation is programmed.
Study: NCT02238912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kandhaga rasayanam
Description: KANDHAGA RASAYANAM is a siddha herbo mineral drug with sulphur as a sole mineral ingredient. It is chosen from the classic Siddha text Siddha Vaidhya Thirattu.
Study: NCT04196140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod Horizon™ Automated Glucose Control System
Description: The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
Study: NCT00885716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient training in shared decision making

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training
Study: NCT01477957

Intervention type: PROCEDURE
Intervention: surgery
Description: biliopancreatic diversion, gastric banding, gastric sleeve resection
Study: NCT05024240

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Stabilometry
Description: Probands will stand on stabilometric platform (double leg stance) and we will measure CoP parameters area and length. We also make this task harder by using foam and exclusion of visual control. Length of one test is 30s.
Study: NCT05024240

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stabilometry
Description: Probands will stand on stabilometric platform (double leg stance) and we will measure CoP parameters area and length. We also make this task harder by using foam and exclusion of visual control. Length of one test is 30s.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Stroop test
Description: There are various names of colours written in non-matching font colour in this test. During this test probands are required to name the colour which is written in text not the colour of the font. We will measure reaction time and number of mistakes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stroop test
Description: There are various names of colours written in non-matching font colour in this test. During this test probands are required to name the colour which is written in text not the colour of the font. We will measure reaction time and number of mistakes.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Backward counting test
Description: In this counting test probands are given number from interval \<180-200\> and they are asked to subtract 7 during 30s interval of the testing. We will measure reaction time and number of mistakes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Backward counting test
Description: In this counting test probands are given number from interval \<180-200\> and they are asked to subtract 7 during 30s interval of the testing. We will measure reaction time and number of mistakes.
Study: NCT02942381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate
Description: 200mg Bid (eGFR\>60 ml/min/1.73m2 ), 100mg Tid(eGFR45-59 ml/min/1.73m2 ), 100mg Bid(eGFR 30-44 ml/min/1.73m2 )

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02247596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 1g tds 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill 1g tds for 2 weeks
Study: NCT04510246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced case management
Description: The health care worker will offer support to the GP for all aspects of the cascade of hepatitis C care including:~* Further testing advice~* Awareness that treatment can be prescribed by the general practitioner~* Conducting pre-treatment work-up assessment~* DAA prescription guidelines, including linkage to specialist consultation~* Providing treatment support~* Advising on testing process for cure~* Advising on post-cure management including methods of follow-up to manage risks (e.g. harm minimisation, reducing re-infection risk, opioid substitution therapy)~* Linking GP to resources for patients with cirrhosis or other concerns to specialist support for ongoing management.~The GP will be offered the option of the DoH specialist to contact the patient directly with the GP's consent to notify them of their result and to educate them on testing and treatment options and referral back to their GP.
Study: NCT03369834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red Light-emitting diode device
Description: The phototherapy will be applied for 3 days followed by a red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrared Light-emitting diode device
Description: The phototherapy will be applied for 3 days followed by a infrared LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.
Study: NCT04604184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: BI 764198

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01813656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
Study: NCT01412541

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Uncoated Angioplasty Balloon
Description: Subjects will be randomized 2:1 to the Moxy Drug Coated Balloon or Standard Angioplasty Balloon

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moxy Drug Coated Balloon
Description: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Study: NCT02873390

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HerinCAR-PD1 cells
Description: herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
Study: NCT01362634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trans-theoretical Process of Change Model-self
Description: self-administered, computer-based intervention
Study: NCT03369834

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrared and Red Light-emitting diode device
Description: The phototherapy will be applied for 3 days followed by a infrared and Red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: LED device off.
Study: NCT01362634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trans-theoretical Process of Change Model - interviewer
Description: interviewer-administered intervention
Study: NCT00978081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid hydrochloride
Description: Patients undergo continuous or fractionated photodynamic therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid hydrochloride
Description: Patients undergo continuous or fractionated photodynamic therapy.
Study: NCT03686709

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Post therapy PET/CT Imaging
Description: whole-body PET/CT following Y90 radioembolization

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Post therapy PET/CT Imaging
Description: whole-body PET/CT following Y90 radioembolization
Study: NCT03932422

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluate if the individuals are resistant hypertensive patients
Description: Evaluation of the individuals has the objective determine if they are resistant hypertensive patients. This is important because the resistant people have worse prognosis than the controlled people and need more attention from the health professionals. Analysis must be done using the ambulatory blood pressure monitoring.
Study: NCT01827722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex
Description: Intravitreal injection of Ozurdex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal Injection of Ranibizumab
Study: NCT04198038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Songwriting with licensed music therapist
Description: Song selected by parent-child dyad with recordings of physiologic components (i.e. heartbeat, breathing)
Study: NCT01431690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: A single 25 mg dose of warfarin
Study: NCT01827722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Ozurdex with Ranibizumab PRN
Description: Intravitreal Injection of combination medication Ozurdex and Ranibizumab
Study: NCT03342898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YF-17D
Description: YF-17D SC injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YF-17D
Description: YF-17D SC injection.
Study: NCT03358303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medly
Description: Medly will enable patients with HF to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
Study: NCT03342898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YF-17D
Description: YF-17D SC injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection.
Study: NCT01431690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omefas
Description: 4 x 1 g capsule dose of Epanova®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3-acid ethyl esters
Description: 4 x 1 g capsule dose of Lovaza®
Study: NCT02697890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDBA (MinerOss®) + Mucograft® seal
Description: Collagen matrix membrane for soft-tissue regeneration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)
Description: Standard of Care
Study: NCT00589134

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gatorade Endurance Formula
Description: carbohydrate electrolyte beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ganirelix acetate
Description: GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days.
Study: NCT01211457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapacitabine and decitabine (Part 1 - completed)
Description: decitabine will be administered in alternating cycles with sapacitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapacitabine and venetoclax (Part 2 - recruiting)
Description: sapacitabine will be administered concomitantly with venetoclax
Study: NCT03124407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin Topical Solution
Description: Over-the-counter Tentative Final Monograph compliant product with 0.25% capsaicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin Topical Solution
Description: Over-the-counter Tentative Final Monograph compliant product with 0.25% capsaicin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drug product vehicle
Description: This is the vehicle for the active treatment drug product, but without capsaicin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drug product vehicle
Description: This is the vehicle for the active treatment drug product, but without capsaicin
Study: NCT04546399

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT
Study: NCT03342898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9% NaCl) SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9% NaCl) SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9% NaCl) SC injection.